TGFB1 and familial pancreatic carcinoma: The administration of nimotuzumab as part of possible multimodal combination of agents that target a subset of cancer-associated fibroblasts or their secreted products (e.g., TGF-β), could be explored as an alternative to overcome the heterogeneity issues of pancreatic cancer.